Dominik Denschlag

Bad Homburg Vor Der Hoehe, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Statement by the Uterus Commission of the Arbeitsgemeinschaft Gynäkologische Onkologie [German Gynecological Oncology Group] (AGO) on the ESGO-ESTRO-ESP Guideline 2025.

Statement by the Uterus Commission of the Arbeitsgemeinschaft Gynäkologische Onkologie [German Gynecological Oncology Group] (AGO) on the ESGO-ESTRO-ESP Guideline 2025.

Journal: Geburtshilfe und Frauenheilkunde

Published: February 03, 2026

Risk for non-sentinel metastases in the contralateral groin in patients with a unilateral positive sentinel lymph node in primary vulvar cancer- a subgroup analysis of the AGO-VOP.2 QS Vulva Study.

Risk for non-sentinel metastases in the contralateral groin in patients with a unilateral positive sentinel lymph node in primary vulvar cancer- a subgroup analysis of the AGO-VOP.2 QS Vulva Study.

Journal: Gynecologic oncology

Published: March 12, 2025

Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus.

Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus.

Journal: Geburtshilfe und Frauenheilkunde

Published: December 19, 2024

Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, June 2024).

Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, June 2024).

Journal: Geburtshilfe und Frauenheilkunde

Published: November 25, 2024

Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators.

Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: September 25, 2024

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 05, 2024

Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.

Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: March 08, 2024

Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on Neoadjuvant Chemotherapy Prior to Definitive Radiochemotherapy in Patients with Locally Advanced Cervical Cancer.

Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on Neoadjuvant Chemotherapy Prior to Definitive Radiochemotherapy in Patients with Locally Advanced Cervical Cancer.

Journal: Geburtshilfe und Frauenheilkunde

Published: February 26, 2024

Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on Surgical Therapy for Patients with Stage IA2-IIB1 Cervical Cancer.

Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on Surgical Therapy for Patients with Stage IA2-IIB1 Cervical Cancer.

Journal: Geburtshilfe und Frauenheilkunde

Published: August 24, 2023

Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on the Use of Primary Chemoimmunotherapy to Treat Patients with Locally Advanced or Recurrent Endometrial Cancer.

Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on the Use of Primary Chemoimmunotherapy to Treat Patients with Locally Advanced or Recurrent Endometrial Cancer.

Journal: Geburtshilfe und Frauenheilkunde

Published: July 07, 2023

Ten recommendations for sarcoma surgery: consensus of the surgical societies based on the German S3 guideline "Adult Soft Tissue Sarcomas".

Ten recommendations for sarcoma surgery: consensus of the surgical societies based on the German S3 guideline "Adult Soft Tissue Sarcomas".

Journal: Langenbeck's archives of surgery

Published: May 07, 2023

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 09, 2023

Showing 1-12 of 36

Last Updated: 09/26/2026